What is the appropriate management for chlorpheniramine toxicity?

Management of Chlorpheniramine Toxicity

Chlorpheniramine toxicity requires supportive care focused on managing anticholinergic symptoms, CNS depression or excitation, cardiovascular effects, and the potentially life-threatening complication of rhabdomyolysis, with immediate consultation of a poison control center or medical toxicologist for severe cases.

Initial Assessment and Stabilization

The provided guidelines do not specifically address chlorpheniramine (an antihistamine) toxicity, as the 2023 AHA focused update covers other poisonings 1. However, timely consultation with a medical toxicologist, clinical toxicologist, or regional poison center facilitates rapid and effective therapy for any critical poisoning 1.

Key Clinical Manifestations to Monitor

Based on documented cases, chlorpheniramine overdose presents with:

• CNS effects: Hallucinations, agitation, delirium, or paradoxically CNS depression and coma 2, 3
• Cardiovascular: Tachycardia, hypertension 2
• Anticholinergic toxidrome: Fever, urinary retention, dry mucous membranes
• Rhabdomyolysis: A critical and potentially fatal complication requiring aggressive intervention 2, 3

Treatment Algorithm

1. Immediate Supportive Care

• Airway protection: Secure airway if altered mental status or respiratory depression occurs
• Gastrointestinal decontamination: Consider activated charcoal if presentation is within 1-2 hours of ingestion and airway is protected 2
• Continuous cardiac monitoring: Watch for dysrhythmias secondary to tachycardia and electrolyte abnormalities

2. Management of Severe Agitation

If the patient develops severe agitation or delirium (common in antihistamine toxicity):

• Administer benzodiazepines as first-line sedation 1
• Avoid physical restraints without adequate sedation, as prolonged restraint use is associated with death in severely agitated patients 1
• Monitor core temperature aggressively, as psychomotor agitation generates heat

3. Rhabdomyolysis Prevention and Treatment

This is the most critical life-threatening complication documented in chlorpheniramine toxicity, with creatine kinase levels reported as high as 195,489 U/L 3:

• Aggressive IV fluid resuscitation: Target urine output of 200-300 mL/hour to prevent acute kidney injury
• Monitor laboratory markers:
  • Creatine kinase (peaks 24-48 hours post-ingestion) 2
  • Myoglobin (may peak earlier, around 6-9 hours) 2
  • Serum creatinine and electrolytes (potassium, calcium, phosphate)
• Maintain electrolyte balance: Correct hypokalemia, hypocalcemia, and hyperphosphatemia
• Consider alkalinization of urine (though not specifically studied in chlorpheniramine toxicity, it's standard for severe rhabdomyolysis)
• Hemodialysis or continuous renal replacement therapy if acute kidney injury develops 3

4. Cardiovascular Management

For tachycardia and hypertension:

• Benzodiazepines are first-line for sympathetic hyperactivity
• Avoid beta-blockers in isolated antihistamine toxicity (may worsen unopposed alpha effects)
• Short-acting agents preferred if additional pharmacologic intervention needed

5. Serotonin Toxicity Consideration

Important caveat: Chlorpheniramine is a potent serotonin reuptake inhibitor 4. If co-ingested with other serotonergic agents (SSRIs, dextromethorphan, tramadol):

• Assess for serotonin toxicity using Hunter Criteria (clonus, hyperreflexia, hyperthermia, agitation)
• Manage with benzodiazepines and aggressive cooling
• Consider cyproheptadine in severe cases (though not addressed in provided guidelines)

Monitoring Parameters

• Vital signs: Every 15-30 minutes initially, focusing on heart rate, blood pressure, temperature, respiratory rate
• Laboratory monitoring:
  • Creatine kinase and myoglobin at presentation, 6 hours, 12 hours, and 24 hours
  • Basic metabolic panel including creatinine
  • Urinalysis for myoglobinuria
  • Cardiac biomarkers if chest pain or ECG changes present
• ECG monitoring: Continuous for dysrhythmias

Disposition

• Admit to ICU if:

  • Altered mental status requiring airway protection
  • Hemodynamic instability
  • Evidence of rhabdomyolysis (CK >5,000 U/L or rising myoglobin)
  • Seizures or severe agitation requiring continuous sedation

• Observation unit for moderate ingestions with mild symptoms and normal laboratory values at 6-8 hours

• Discharge only after 6-8 hours of observation with normal vital signs, resolving symptoms, and normal initial laboratory screening including CK

Critical Pitfalls to Avoid

1. Underestimating rhabdomyolysis risk: Even with moderate ingestions (400 mg documented to cause rhabdomyolysis) 2, aggressive monitoring is essential
2. Delayed fluid resuscitation: Start aggressive hydration immediately if any elevation in CK or myoglobin
3. Missing co-ingestions: Chlorpheniramine is often combined with dextromethorphan, increasing serotonin toxicity risk 4
4. Using physostigmine: While tempting for anticholinergic symptoms, it carries seizure risk and is not recommended without toxicology consultation

The absence of specific antidote makes supportive care and complication prevention the cornerstone of management 1.